The Emerging Role of Nanoparticles Combined with Either Radiotherapy or Hyperthermia in Head and Neck Cancer: A Current Review DOI Open Access

Elena Vlastou,

Andromachi Kougioumtzopoulou, Kalliopi Platoni

et al.

Cancers, Journal Year: 2025, Volume and Issue: 17(5), P. 899 - 899

Published: March 6, 2025

Head and neck cancer (HNC) includes various malignancies represents the seventh most common worldwide. The early diagnosis of HNC results in a 70-90% five-year survival rate, which declines with locally advanced stages disease. Current care employs multimodal strategy encompassing surgery, radiation therapy (RT), chemotherapy, immunotherapy, while treatment options vary according to stage, tumor features, patient characteristics. About 75% patients will benefit from RT, either as primary or adjuvant following surgical resection. Technological improvements such intensity-modulated RT (IMRT) image-guided (IGRT), have enhanced targeting minimized adjacent healthy tissue irradiation also expanding recurrent metastatic setting. Innovative therapeutic strategies for integrate gene therapy, molecular targeted photodynamic photothermal nanoparticles (NPs), objective optimizing control reducing damage normal tissues. NPs are emerging possible radiosensitizers treatment, enhancing efficacy immunotherapy. In vivo vitro studies on tumors containing gold (Au), gadolinium (Gd), hafnium oxide (HfO2) show promising destruction rates, indicating their potential clinical application. Hyperthermia, investigated an adjunct potentially improves outcomes when combined advancements nanotechnology renewing interest this approach HNC. At present, NBTXR3 is sole NP that being trials enhancement RT.

Language: Английский

The Emerging Role of Nanoparticles Combined with Either Radiotherapy or Hyperthermia in Head and Neck Cancer: A Current Review DOI Open Access

Elena Vlastou,

Andromachi Kougioumtzopoulou, Kalliopi Platoni

et al.

Cancers, Journal Year: 2025, Volume and Issue: 17(5), P. 899 - 899

Published: March 6, 2025

Head and neck cancer (HNC) includes various malignancies represents the seventh most common worldwide. The early diagnosis of HNC results in a 70-90% five-year survival rate, which declines with locally advanced stages disease. Current care employs multimodal strategy encompassing surgery, radiation therapy (RT), chemotherapy, immunotherapy, while treatment options vary according to stage, tumor features, patient characteristics. About 75% patients will benefit from RT, either as primary or adjuvant following surgical resection. Technological improvements such intensity-modulated RT (IMRT) image-guided (IGRT), have enhanced targeting minimized adjacent healthy tissue irradiation also expanding recurrent metastatic setting. Innovative therapeutic strategies for integrate gene therapy, molecular targeted photodynamic photothermal nanoparticles (NPs), objective optimizing control reducing damage normal tissues. NPs are emerging possible radiosensitizers treatment, enhancing efficacy immunotherapy. In vivo vitro studies on tumors containing gold (Au), gadolinium (Gd), hafnium oxide (HfO2) show promising destruction rates, indicating their potential clinical application. Hyperthermia, investigated an adjunct potentially improves outcomes when combined advancements nanotechnology renewing interest this approach HNC. At present, NBTXR3 is sole NP that being trials enhancement RT.

Language: Английский

Citations

0